EICHOR
● Recruiting
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Condition: Epidermal Growth Factor · Epidermal Growth Factor Receptor · Epidermal Growth Factor Receptor Gene Mutation · Sponsor: EpiBiologics
About this study
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
This description comes directly from the study's public registry record.
Talk to the study team
EpiBiologics Clinical Trials · 650-955-7486 · clinicaltrials@epibiologics.com
Always discuss trial participation with your own doctor first.
Locations (6)
| START Los Angeles | Los Angeles, California, United States | Recruiting |
| Astera Cancer Care | East Brunswick, New Jersey, United States | Recruiting |
| START New York Long Island | Lake Success, New York, United States | Recruiting |
| Sarah Cannon and HCA Research Institute | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| South Texas Accelerated Research Therapeutics (START) | San Antonio, Texas, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.